Iktos, a Paris, France-based company specializing in artificial intelligence for new drug discovery, raised €15.5M in Series A funding.
The round was led by M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital.
The company intends to use the funds to expand its AI technology platform, launch Iktos Robotics, an AI-driven automated end-to-end drug discovery service, and extend the application of its solutions to biological products (peptides, antibodies, etc.).
Led by Yann Gaston-Mathé, President, Iktos is a startup specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically to medicinal chemistry and new drug design. The company develops a proprietary solution based on generative learning models, which allows, from existing data, to design optimized molecules in silico to meet all the success criteria of a small molecule discovery project. The use of its technology platform enables productivity gains in upstream pharmaceutical R&D. The company offers its technology both as professional services and as a SaaS software platform, Makya. Iktos also develops Spaya, a synthesis planning software based on Iktos’ proprietary AI technology for retrosynthesis.
The company has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies such as Chiesi Group, Galapagos, Janssen, Merck, Teijin, Ono Pharmaceuticals, Pfizer, Servier, UCB.
FinSMEs
09/03/2023